Enzyme Shapes Pancreatic Tumor Signals in Lab Study
Laboratory research suggests a possible new target for pancreatic cancer, but the findings have not been tested in patients.
Updated on Nov. 1, 2026 in Cancer
Researchers reported that the enzyme DYRK1A helps control signaling molecules that shape the environment around pancreatic tumors, in a laboratory study. The work is preclinical and has not yet been tested in patients.
Why it matters
Pancreatic cancer is hard to treat partly because the tumor is surrounded by supporting cells and signals that help it grow and draw in immune cells. Identifying a regulator of those signals offers a potential new target, though any clinical benefit remains unknown.
This preclinical laboratory study used quantitative mass spectrometry to profile secreted proteins from DYRK1A-depleted pancreatic cancer cells and cancer-associated fibroblasts. The results show that reducing DYRK1A lowered several secreted signaling factors and impaired immune cell migration in culture, but the work has not been tested in patients.
The details
DYRK1A is an enzyme found in both pancreatic cancer cells and the fibroblasts that surround them, and it appears at comparable levels in each. Earlier work had shown it promotes tumor growth by stabilizing the c-MET protein in cancer cells. In this study, blocking DYRK1A reduced secretion of CCL2, CCL5 and CSF-1 from cancer cells and CXCL12 from fibroblasts, signals that recruit immune cells. Combining proteins regulated by DYRK1A in both compartments pointed to pathways involved in immune infiltration and cell-to-cell interaction.
Timeline
No specific dates for the study were provided in the source material.
Health Landscape
Pancreatic ductal adenocarcinoma is among the cancers with the poorest treatment outcomes, and much of its resistance is attributed to the dense stromal environment built by cancer-associated fibroblasts. Targeting the signals that shape this environment is an active area of research, and DYRK1A is now one candidate regulator under study.
This is early laboratory research, so it does not change current pancreatic cancer screening or treatment. Anyone with questions about their own risk or care should raise them with an oncologist or primary care physician.
The takeaway
Research into the tumor environment is opening new questions about pancreatic cancer, but findings from cell studies take years to reach patients. Readers interested in cancer research updates can follow reputable cancer institutes and discuss any personal concerns with their doctor.
Further reading
For more on how tumors are studied and treated, explore our Cancer coverage.
